- Report
- October 2024
- 196 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Training
- March 2025
- 2 Days
Global
From €1453EUR$1,597USD£1,246GBP
- Report
- February 2024
- 116 Pages
China
From €2594EUR$2,850USD£2,224GBP
- Drug Pipelines
- December 2022
- 30 Pages
United States
From €2958EUR$3,250USD£2,536GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2958EUR$3,250USD£2,536GBP
- Training
- December 2023
- 2 Days
Global
From €1677EUR$1,843USD£1,438GBP
- Report
- October 2022
- 119 Pages
Global
From €3185EUR$3,500USD£2,731GBP
- Book
- February 2023
- 576 Pages
- Book
- April 2022
- 480 Pages
- Book
- April 2022
- 496 Pages
- Book
- December 2021
- 624 Pages
- Book
- January 2013
- 632 Pages
- Book
- February 2024
- 928 Pages

The Oral Bioavailability market is a subset of the Drug Delivery market, which focuses on the delivery of drugs to the body through various means. Oral bioavailability is the measure of how much of a drug is absorbed into the bloodstream when taken orally. This is important for drug efficacy, as it determines how much of the drug is available to the body for therapeutic use.
Oral bioavailability is affected by a variety of factors, including the drug's solubility, permeability, and metabolism. To improve bioavailability, drug delivery systems such as liposomes, nanoparticles, and microemulsions are used to increase the drug's solubility and permeability.
Companies in the Oral Bioavailability market include Novartis, Pfizer, Merck, and AstraZeneca. Other companies include GlaxoSmithKline, Sanofi, and Johnson & Johnson. Show Less Read more